×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LXRX – lexicon pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LXRX
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/20
04:15 pm
lxrx
Lexicon Appoints Ivan H. Cheung to Board of Directors [Yahoo! Finance]
Medium
Report
Lexicon Appoints Ivan H. Cheung to Board of Directors [Yahoo! Finance]
11/20
04:05 pm
lxrx
Lexicon Appoints Ivan H. Cheung to Board of Directors
Medium
Report
Lexicon Appoints Ivan H. Cheung to Board of Directors
11/18
08:35 am
lxrx
Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week [Yahoo! Finance]
11/14
08:12 am
lxrx
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago [Yahoo! Finance]
Low
Report
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association's (AHA) Sessions 2024 in Chicago [Yahoo! Finance]
11/14
08:00 am
lxrx
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago
Low
Report
Post-Hoc Analysis Demonstrating Sotagliflozin Benefits Across Broad Spectrum of Heart Failure Patient Populations is Among Four Lexicon-Supported Presentations at the American Heart Association’s (AHA) Sessions 2024 in Chicago
11/13
08:06 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
11/13
08:05 am
lxrx
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
11/13
02:32 am
lxrx
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]
Medium
Report
Lexicon Pharmaceuticals Inc (LXRX) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst ... [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/12/2024
04:05 pm
LXRX
lexicon pharmaceuticals, inc.
MISS
Report
-8.4%
lexicon pharmaceuticals, inc.
8/1/2024
04:00 pm
LXRX
lexicon pharmaceuticals, inc.
BEAT
Report
-16.1%
lexicon pharmaceuticals, inc.
5/2/2024
04:05 pm
LXRX
lexicon pharmaceuticals, inc.
MISS
Report
1.2%
lexicon pharmaceuticals, inc.
3/11/2024
07:15 am
LXRX
lexicon pharmaceuticals, inc.
BEAT
Report
8.1%
lexicon pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/20
04:07 pm
lxrx
Form 8-K LEXICON PHARMACEUTICALS, For: Nov 19
Medium
Report
Form 8-K LEXICON PHARMACEUTICALS, For: Nov 19
11/14
04:26 pm
lxrx
Form SC 13G/A LEXICON PHARMACEUTICALS, Filed by: BIOTECHNOLOGY VALUE FUND L P
Medium
Report
Form SC 13G/A LEXICON PHARMACEUTICALS, Filed by: BIOTECHNOLOGY VALUE FUND L P
11/13
07:13 am
lxrx
Form 10-Q LEXICON PHARMACEUTICALS, For: Sep 30
Medium
Report
Form 10-Q LEXICON PHARMACEUTICALS, For: Sep 30
11/12
04:07 pm
lxrx
Form 8-K LEXICON PHARMACEUTICALS, For: Nov 12
Medium
Report
Form 8-K LEXICON PHARMACEUTICALS, For: Nov 12
11/12
10:32 am
lxrx
Form SC 13G/A LEXICON PHARMACEUTICALS, Filed by: FMR LLC
Low
Report
Form SC 13G/A LEXICON PHARMACEUTICALS, Filed by: FMR LLC
10/16
04:37 pm
lxrx
Form 8-K LEXICON PHARMACEUTICALS, For: Oct 16
Low
Report
Form 8-K LEXICON PHARMACEUTICALS, For: Oct 16
10/7
04:59 pm
lxrx
Form 3 LEXICON PHARMACEUTICALS, For: Oct 02 Filed by: DeFrancesco Lisa
Low
Report
Form 3 LEXICON PHARMACEUTICALS, For: Oct 02 Filed by: DeFrancesco Lisa
9/16
06:52 am
lxrx
Form 8-K LEXICON PHARMACEUTICALS, For: Sep 13
Low
Report
Form 8-K LEXICON PHARMACEUTICALS, For: Sep 13
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
12/2
Lexicon Pharmaceuticals stock slides 15% premarket after FDA denies appeal of decision relating to diabetes drug [MarketWatch]
58.0%
9/17 Form 4 LEXICON PHARMACEUTICALS, For: Sep 13 Filed by: SOBECKI CHRISTOPHER J 27.9%
9/10 Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting 27.9%
8/8 Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes 15.0%
4/24 Form 4 LEXICON PHARMACEUTICALS, For: Apr 22 Filed by: MAIN ALAN J 11.6%
8/2 Form 4 LEXICON PHARMACEUTICALS, For: Aug 02 Filed by: BARKER SAM L 10.8%
7/29 Here's Why Lexicon Pharmaceuticals Is Collapsing Today [The Motley Fool] 8.7%
12/5 Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211 7.4%
6/27 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.2%
10/31 Lexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019 6.3%
9/17 Form 4 LEXICON PHARMACEUTICALS, For: Sep 13 Filed by: SOBECKI CHRISTOPHER J 27.9%
9/10 Lexicon Pharmaceuticals to Present Sotagliflozin Clinical Data at the European Association for the Study of Diabetes 55th Annual Meeting 27.9%
8/8 Lexicon Pharmaceuticals Announces Publication of Positive Data for Zynquista™ (Sotagliflozin) on Cardiorenal Clinical Biomarkers in Adults With Type 1 Diabetes 15.0%
4/24 Form 4 LEXICON PHARMACEUTICALS, For: Apr 22 Filed by: MAIN ALAN J 11.6%
8/2 Form 4 LEXICON PHARMACEUTICALS, For: Aug 02 Filed by: BARKER SAM L 10.8%
7/29 Here's Why Lexicon Pharmaceuticals Is Collapsing Today [The Motley Fool] 8.7%
12/5 Lexicon Pharmaceuticals Announces Positive Topline Phase 1 Data for LX9211 7.4%
6/27 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.2%
10/31 Lexicon Pharmaceuticals to Host Third Quarter 2019 Financial Results Conference Call and Webcast on November 7, 2019 6.3%
TOP News Decliners
7/26
Lexicon Pharmaceuticals Provides Preliminary Update for Zynquista™ (Sotagliflozin) Type 2 Diabetes Phase 3 Program
-43.7%
7/31 Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update -21.1%
3/19 LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM -15.9%
4/28 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -14.9%
3/12 Q4/2019 12/31/2019 EPS -0.480 ZacksConsensus -0.760 ActVsEst 0.280 - Beat -11.9%
11/7 Form S-3 LEXICON PHARMACEUTICALS, -11.6%
9/19 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.6%
12/2 Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA’s Office of New Drugs for Sotagliflozin in Type 1 Diabetes -10.5%
8/1 Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30 -9.1%
4/15 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock. -9.0%
7/31 Lexicon Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides a Business Update -21.1%
3/19 LEXICON PHARMACEUTICALS PROVIDES AN UPDATE ON THE SOTAGLIFLOZIN TYPE 2 DIABETES PROGRAM -15.9%
4/28 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -14.9%
3/12 Q4/2019 12/31/2019 EPS -0.480 ZacksConsensus -0.760 ActVsEst 0.280 - Beat -11.9%
11/7 Form S-3 LEXICON PHARMACEUTICALS, -11.6%
9/19 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was downgraded by analysts at ValuEngine from a "hold" rating to a "sell" rating. -10.6%
12/2 Lexicon Pharmaceuticals Receives Formal Dispute Resolution Request Decision From FDA’s Office of New Drugs for Sotagliflozin in Type 1 Diabetes -10.5%
8/1 Form 10-Q LEXICON PHARMACEUTICALS, For: Jun 30 -9.1%
4/15 Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $2.50 price target on the stock. -9.0%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: